- Home
- MARPS vs PPBT Comparison
MARPS vs PPBT Comparison
Compare MARPS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | PPBT |
|---|---|---|
| Founded | 1956 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 4.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MARPS | PPBT |
|---|---|---|
| Price | $4.95 | $4.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 22.4K | 11.2K |
| Earning Date | 02-13-2026 | 05-20-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $0.41 |
| 52 Week High | $6.49 | $5.18 |
Technical Indicators
Market Signals| Indicator | MARPS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 52.48 |
| Support Level | $4.22 | $3.70 |
| Resistance Level | $5.23 | $4.39 |
| Average True Range (ATR) | 0.19 | 0.34 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 56.23 | 40.35 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.